<DOC>
	<DOCNO>NCT01808573</DOCNO>
	<brief_summary>This randomize , multi-center , multinational , open-label , active-controlled , parallel design study combination neratinib plus capecitabine versus combination lapatinib plus capecitabine HER2+ MBC patient receive two prior HER2 direct regimen metastatic setting .</brief_summary>
	<brief_title>A Study Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine Patients With HER2+ Metastatic Breast Cancer Who Have Received Two More Prior HER2 Directed Regimens Metastatic Setting</brief_title>
	<detailed_description>This randomize , multi-center , multinational , open-label , active-controlled , parallel design study combination neratinib plus capecitabine versus combination lapatinib plus capecitabine HER2+ MBC patient receive two prior HER2 direct regimen metastatic setting . Patients randomize 1:1 ratio one follow treatment arm : - Arm A : neratinib ( 240 mg daily ) + capecitabine ( 1500 mg/m^2 daily , 750 mg/m^2 twice daily [ BID ] ) - Arm B : lapatinib ( 1250 mg daily ) + capecitabine ( 2000 mg/m^2 daily , 1000 mg/m^2 BID ) Patients receive either neratinib plus capecitabine combination lapatinib plus capecitabine combination occurrence death , disease progression , unacceptable toxicity , specify withdrawal criterion .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Aged â‰¥18 year sign informed consent . Histologically confirm MBC , current stage IV . Documented HER2 overexpression geneamplified tumor ( immunohistochemistry [ IHC ] 3+ IHC 2+ confirmatory fluorescence situ hybridization [ FISH ] + ) . Prior treatment least two ( 2 ) HER2directed regimen metastatic breast cancer . Received previous therapy capecitabine , neratinib , lapatinib , HER2 direct tyrosine kinase inhibitor . Note : There additional inclusion exclusion criterion . The study center determine meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>